Viamet Pharmaceuticals Reports Additional Positive Interim Results Of Phase 2 Study Of VT-1161 In Patients With Moderate To Severe Acute Vulvovaginal Candidiasis

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Viamet Pharmaceuticals, Inc. today reported additional positive interim results from its ongoing Phase 2a study of VT-1161, the Company’s lead novel, oral antifungal compound, in patients with moderate to severe acute vulvovaginal candidiasis (AVVC), commonly known as vaginal yeast infection. The additional data being reported today are for the highest dose of VT-1161 in the study. These data provide additional strong evidence of clinical antifungal activity and a favorable safety profile for VT-1161 in treating vaginal Candida infections. Based on these positive results, the company expects to begin Phase 2b clinical trials for VT-1161 in patients with recurrent vulvovaginal candidiasis (RVVC) in the second half of 2014.

Help employers find you! Check out all the jobs and post your resume.

Back to news